Free Trial
NASDAQ:AXSM

Axsome Therapeutics Q2 2025 Earnings Report

Axsome Therapeutics logo
$103.02 +1.64 (+1.62%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$104.02 +1.01 (+0.98%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.04
Beat/Miss
N/A
One Year Ago EPS
N/A

Axsome Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$140.02 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Axsome Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 4, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Axsome Therapeutics Earnings Headlines

A Look at Axsome Therapeutics's Upcoming Earnings Report
Q3 EPS Estimate for Axsome Therapeutics Increased by Analyst
China just unlocked Nvidia’s AI chips—what that means for you
Tired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system tracks breaking AI news and shows when to trade.📈 AI-backed. Beginner-friendly. Results proven.
See More Axsome Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Axsome Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Axsome Therapeutics and other key companies, straight to your email.

About Axsome Therapeutics

Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

View Axsome Therapeutics Profile

More Earnings Resources from MarketBeat